Based on published information, we predicted that bortezomib may partially counteract the molecular mechanism of action of ibrutinib in MM cells, because it induces NF-κB activation in MM cells [18], while ibrutinib acts, at least partially, through NF-κB inhibition in MM [26]. Here, NFKB1 is linked to Miyoshi myopathy.